Related Experiment Video

Updated: May 18, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathway

Giacomo Cossa1, Laura Gatti, Giuliana Cassinelli

  • 1Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCSS Istituto Nazionale dei Tumori, via Amadeo 42, 20133 Milan, Italy.

Current Pharmaceutical Design
|September 15, 2012
PubMed

Insights

Mitogen-activated protein kinases (MAPK) regulate cell processes and are implicated in cancer. Targeting the Extracellular Signal-Regulated Kinases (ERK) pathway may overcome drug resistance in cancer treatment.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Mitogen-activated protein kinases (MAPK) regulate crucial cellular functions like proliferation and survival.
  • Aberrant MAPK pathway activation is observed in various human tumors, often due to receptor tyrosine kinase deregulation or pathway component mutations.
  • Understanding the MAPK network has spurred the development of targeted clinical therapies.

Purpose of the Study:

  • To explore the role of MAPK signaling in tumor cell response and resistance to anticancer agents.
  • To investigate the potential of targeting the Extracellular Signal-Regulated Kinases (ERK) cascade to modulate sensitivity to antitumor treatments.
  • To highlight the significance of drug combinations involving ERK pathway inhibitors for overcoming resistance.

Main Methods:

  • Review of molecular characterization of the MAPK pathway.
  • Analysis of preclinical studies on MAPK inhibitors and drug combinations.
  • Examination of the interplay between ERK signaling and tumor cell survival pathways.

Main Results:

  • MAPK pathway activation is linked to tumor development and influences response to anticancer drugs.
  • The Extracellular Signal-Regulated Kinases (ERK) cascade can promote tumor cell survival and mediate resistance to both cytotoxic and targeted therapies.
  • Preclinical data suggest that combining ERK inhibitors with conventional or targeted agents can enhance treatment efficacy.

Conclusions:

  • Targeting the ERK cascade is a promising strategy to sensitize tumors to anticancer agents.
  • Drug combinations involving ERK pathway inhibitors hold potential for overcoming drug resistance.
  • Further research into tumor genetic alterations and resistance mechanisms is crucial for designing effective MAPK-mediated combination therapies.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...